Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
Tourmaline Bio, Inc. (TRML)
Company Research
Source: GlobeNewswire
NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, will present at the in the following investor conference: Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceFireside chat February 7, 2024 at 11:00am ET A live webcast and replay will be under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at https://ir.tourmalinebio.com. About Tourmaline Bio, Inc. Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. About TOUR006TOUR006 is a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class p
Show less
Read more
Impact Snapshot
Event Time:
TRML
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRML alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRML alerts
High impacting Tourmaline Bio, Inc. news events
Weekly update
A roundup of the hottest topics
TRML
News
- Tourmaline Bio, Inc. (NASDAQ: TRML) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $74.00 price target on the stock.MarketBeat
- Tourmaline Bio, Inc. (NASDAQ: TRML) had its price target raised by analysts at Jefferies Financial Group Inc. from $41.00 to $72.00. They now have a "buy" rating on the stock.MarketBeat
- Tourmaline Bio, Inc. (NASDAQ: TRML) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $48.00 price target on the stock.MarketBeat
- Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsGlobeNewswire
- Tourmaline Bio to Present at Upcoming Investor ConferencesGlobeNewswire
TRML
Earnings
- 11/14/23 - Miss
TRML
Analyst Actions
- 3/20/24 - HC Wainwright